FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 346:56-58 January 3, 2002 Number 1 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Csernansky, J. G. PubMed Citation

Schizophrenia is a devastating mental disorder and a leading cause of disability.¹ It affects between 0.4 and 1.4 percent of people during their lives,² usually beginning in adolescence or early adulthood; less than 20 percent of patients maintain full recovery after the first episode.² Drug treatment and psychosocial interventions such as family and cognitive therapy³ are the main approaches to preventing relapses. Conventional antipsychotic drugs such as chlorpromazine and haloperidol were introduced in the 1950s and are effective in treating acute psychotic symptoms and in preventing relapse.^3,4 The prevention of relapse, however, requires prolonged or even lifelong therapy, which means . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Tiihonen, J., Walhbeck, K., Lonnqvist, J., Klaukka, T., Ioannidis, J. P A, Volavka, J., Haukka, J. (2006). Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. BMJ 333: 224- [Abstract] [Full Text]  
• Burns, T., THE UK SCHIZOPHRENIA CARE AND ASSESSMENT PROGRAMME, (2006). NICE guidance in schizophrenia: how generalisable are drug trials?. Psychiatr. Bull. 30: 210-212 [Abstract] [Full Text]